

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-10 (Cancelled).

11. (Currently Amended) A method of promoting the healing of a wound, or fibrotic disorder, with reduced scarring, the method comprising administering to a patient in need thereof an amount of an agent selected from the group consisting of:

- i) human IL-10, and
 - ii) ~~a fragment of human IL-10 that retains the anti-inflammatory healing functionality of human IL-10, and~~
 - iii) a partially modified form of human IL-10, or a fragment thereof, that has at least ~~60%~~ 95% homology with human IL-10 and that retains the anti-inflammatory healing functionality of human IL-10,
- sufficient to effect said promotion with reduced scarring.

12. (Previously Presented) The method according to claim 11, wherein the agent is administered in conjunction with a pharmaceutically acceptable carrier, diluent or excipient.

13. (Previously Presented) The method according to claim 11, wherein the agent is administered in conjunction with a composition for promoting the healing of wounds with reduced scarring.

14. (Previously Presented) The method according to claim 11, wherein the agent is administered in conjunction with a composition for promoting the healing of chronic wounds.

15. (Previously Presented) The method according to claim 11, wherein the agent is administered to a wound site or site of a fibrotic disorder.

16. (Previously Presented) The method according to claim 11, wherein the agent is administered at a concentration of between about 1 μ M and about 10 μ M.

17. (Previously Presented) The method according to claim 16, wherein the agent is administered at a concentration of between about 2.5 μ M and about 5 μ M.

18. and 19. (Cancel).